Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Research Council grant · Running

COMPASS Deciphering the COMPASS that guides cancer

Coordinator
Universite Libre De Bruxelles, Belgium
Runs
1 October 2025 to 30 September 2030
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101221941

What the project is doing

In the project's own words, from its summary on CORDIS.

Epigenetic features are commonly dysregulated in cancer and one of the surprising findings from the sequencing of cancer genomes is the high rate of alterations in many epigenetic regulators. KMT2D/MLL4, KMT2C/MLL3 and KDM6A/UTX are among the most frequently mutated genes in a wide range of cancers and in normal aged epithelial cells. Interestingly, these three genes are components of the same complex, COMPASS-like complex that regulate enhancer activity and regulate gene expression in a lineage specific manner.

The deletion of members of the COMPASS-like complex has been associated with altered differentiation, aging and tumorigenesis. However, the precise mechanisms by which mutations in these genes impact cell states during tissue homeostasis, tumour initiation, tumour heterogeneity and metastasis, remain poorly understood. To address these important questions, we will use multidisciplinary approaches that will combine in vivo single cell lineage tracing, single-cell genomics, epigenomics and transcriptomics, in vivo CRISPR-based gene editing, together with genetic and pharmacologic perturbations, to define in a comprehensive and integrated manner the impact of Kmt2d, Kmt2c and Kdm6a deletion on cell state dynamics during homeostasis, regeneration, early steps of tumour initiation, tumour heterogeneity and metastasis in skin squamous cell carcinoma and bladder cancer.

Moreover, we will perform genome wide CRISPR-Cas9 screen to identify the synthetically lethal genes in KMT2D, KMT2C and KDM6A mutated cancer cells to uncover new tumour vulnerabilities that can be pharmacologically targeted.

Topics

Who is involved

OrganisationCityCountryRole
Universite Libre De BruxellesBruxellesBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI